Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1)

NCT03474744 is registered in ClinicalTrials.gov with Christian Buske as lead sponsor.

NCT NCT03474744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1)
Lead sponsor
Christian Buske
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2019
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma